Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Surg Neurol Int ; 9: 173, 2018.
Article in English | MEDLINE | ID: mdl-30210906

ABSTRACT

BACKGROUND: The appearance of edematous lesions in the subacute phase is a rare complication following neuroendovascular therapy. Effective management of these lesions remains unclear. In this report, a case with progressive edematous lesions in the subacute phase after neuroendovascular therapy was described, and the clinical features and therapeutic strategies were discussed. CASE DESCRIPTION: A 54-year-old female with a large, right cavernous internal carotid artery aneurysm was treated with a flow diverter. Left hemiparesis developed 15 days after the procedure, and multiple edematous lesions in areas of prior catheter procedures were revealed on radiological findings. Steroid pulse therapy was employed, and the lesions were gradually reduced without any additional neurological deficits. No recurrence was recognized in the follow-up study. CONCLUSION: In some reports, pathological findings indicate that these lesions result from the presence of foreign bodies, and emboli could be caused by cotton fibers or hydrophilic polymers used as surface coatings on endovascular catheters. In this case, the edematous lesions were most likely caused by hydrophilic polymer emboli. Steroid pulse therapy had a beneficial effect on the lesions. It is important to effectively manage prescribed periods after the procedure to avoid such a rare complication.

2.
Intern Med ; 57(22): 3313-3316, 2018 Nov 15.
Article in English | MEDLINE | ID: mdl-29984750

ABSTRACT

We herein report the case of stiff-person syndrome in a 73-year-old woman. She experienced episodes of painful muscle spasms and was admitted to another hospital. She was diagnosed with Waldenström macroglobulinemia. She showed improvement in muscle spasms post-chemotherapy, which was discontinued due to pancytopenia. Six months later, she was admitted to our hospital for repeated whole-body muscle spasms, at which point she was diagnosed with stiff-person syndrome. An anti-glutamic acid decarboxylase antibody text was negative. Her muscle spasms disappeared after the administration of corticosteroids and rituximab. Stiff-person syndrome may develop with Waldenström macroglobulinemia. In the present case, corticosteroids and rituximab provided effective treatment.


Subject(s)
Rituximab/therapeutic use , Stiff-Person Syndrome/complications , Waldenstrom Macroglobulinemia/complications , Aged , Drug Therapy, Combination , Female , Glucocorticoids/therapeutic use , Humans , Immunologic Factors/therapeutic use , Stiff-Person Syndrome/drug therapy , Waldenstrom Macroglobulinemia/drug therapy
3.
Cerebellum ; 15(2): 190-200, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26093615

ABSTRACT

To identify the most sensitive scale for use in clinical trials on multiple system atrophy (MSA), a short and sensitive scale is needed for MSA clinical trials. Potential candidates are the Unified MSA Rating Scale (UMSARS), Scale for the Assessment and Rating of Ataxia (SARA), Berg Balance Scale (BBS), MSA Health-Related Quality of Life scale (MSA-QoL), and Scales for Outcomes in Parkinson's Disease-Autonomic questionnaire (SCOPA-AUT). We enrolled patients with MSA from eight hospitals in Hokkaido, Japan. Board-certified neurologists assessed each patient at 6-month intervals and scored them on the UMSARS, SARA, BBS, MSA-QoL, and SCOPA-AUT. Score changes were evaluated using the standardized response mean (SRM). The correlation between disease duration and each score was examined. The first evaluation was conducted on 85 patients (60 patients with MSA cerebellar ataxia dominant subtype [MSA-C] and 25 patients with MSA Parkinsonism-dominant subtype [MSA-P]). Sixty-nine patients were examined after 6 months and 63 patients after 12 months. The UMSARS Part 4 had the largest SRM after 6 months and the SARA after 12 months. SRMs for MSA-P, the shorter duration group, and the early-onset group were larger than were those for MSA-C, the longer duration group, and the late-onset group. SRMs for items regarding skilled hand activities, walking, and standing were relatively large. Our study indicates that the UMSARS (parts 2 and 4), SARA, and BBS are sensitive scales for evaluating MSA progression over 12 months. Items with large SRMs effectively evaluated short-term changes.


Subject(s)
Multiple System Atrophy/diagnosis , Adult , Aged , Disability Evaluation , Disease Progression , Female , Humans , Male , Middle Aged , Multiple System Atrophy/physiopathology , Quality of Life , Severity of Illness Index , Surveys and Questionnaires , Symptom Assessment/methods , Time Factors
4.
Intern Med ; 52(9): 969-72, 2013.
Article in English | MEDLINE | ID: mdl-23648715

ABSTRACT

OBJECTIVE: Neuromyelitis optica (NMO) is an inflammatory disease that affects the optic nerve and spinal cord. Optic neuritis and longitudinally extensive myelitis associated with systemic autoimmune disease have been recently defined as NMO spectrum disorder (NMOSD). In this study, we report the efficacy of intravenous cyclophosphamide (IVCY) therapy for NMOSD. METHODS: Four patients diagnosed with NMOSD were enrolled in this study. The expanded disability status scale (EDSS) score was used to evaluate the degree of severity. All of the patients received intravenous methylprednisolone (IVMP; 1 g/day for three days), and two patients also received plasmapheresis (PP). All of the patients were administered IVCY treatment. RESULTS: Anti-AQP4 antibodies were present in the sera of all patients. All patients exhibited longitudinally extensive transverse myelitis (LETM). Only one patient who fulfilled the criteria for a diagnosis of NMO exhibited optic neuritis. Two patients developed relapse under treatment with low-dose prednisolone (PSL) before the administration of IVCY. The patients in this study exhibited a median improvement in the EDSS score following IVCY treatment from 8.0 to 5.75. Adverse effects were observed in only one patient. CONCLUSION: This study, despite its retrospective design, demonstrated the therapeutic efficacy of IVCY for NMOSD in both the acute and chronic phases of the disease and determined the IVCY dosage for Japanese women with NMOSD. Additionally, this study provided evidence that for NMOSD patients with severe disabilities, IVCY added to IVMP and PP may be a useful therapeutic modality.


Subject(s)
Cyclophosphamide/therapeutic use , Myelitis/drug therapy , Neuromyelitis Optica/drug therapy , Adult , Aquaporin 4/immunology , Autoantibodies/blood , Autoantibodies/immunology , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Disability Evaluation , Drug Evaluation , Female , Humans , Infusions, Intravenous , Magnetic Resonance Imaging , Methylprednisolone/administration & dosage , Methylprednisolone/therapeutic use , Middle Aged , Myelitis/immunology , Myelitis/therapy , Neuromyelitis Optica/immunology , Neuromyelitis Optica/therapy , Plasmapheresis , Retrospective Studies , Severity of Illness Index , Syndrome , Treatment Outcome , Young Adult
5.
J Neurol ; 258(12): 2163-7, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21553080

ABSTRACT

The diagnosis of neurosarcoidosis is often difficult; the imaging signs of spinal cord sarcoidosis sometimes mimic those of cervical spondylotic myelopathy, which is common in elderly persons. We examined the characteristics of spinal cord sarcoidosis in Japanese patients with neurosarcoidosis. This case series identified patients with neurosarcoidosis at four general hospitals and one university hospital from April 1998 to September 2010. All diagnoses were based on the diagnostic criteria proposed by Zajicek et al. Seventeen patients (nine men and eight women) were involved: six patients with spinal cord lesions accompanied by cervical spondylosis, five with cerebral lesions, three with cranial nerve lesions, two with meningitis, and one with nerve root lesions. Patients with spinal cord sarcoidosis had a higher onset age, longer duration from onset to diagnosis, reduced leukocytosis in the cerebrospinal fluid (CSF), and lower angiotensin-converting enzyme (ACE) levels in the CSF. The results of this study indicate that diagnosis of spinal cord sarcoidosis requires careful evaluation.


Subject(s)
Central Nervous System Diseases/cerebrospinal fluid , Sarcoidosis/cerebrospinal fluid , Spinal Cord Diseases/cerebrospinal fluid , Spinal Cord Diseases/diagnosis , Adrenal Cortex Hormones/therapeutic use , Adult , Age of Onset , Aged , Central Nervous System Diseases/diagnosis , Central Nervous System Diseases/drug therapy , Female , Humans , Immunosuppressive Agents/therapeutic use , Male , Methotrexate/therapeutic use , Middle Aged , Peptidyl-Dipeptidase A/cerebrospinal fluid , Retrospective Studies , Sarcoidosis/diagnosis , Sarcoidosis/drug therapy , Spinal Cord Diseases/drug therapy , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...